All Journals > The Journal of Infectious Diseases > 15 April 2008 > Outcomes in SMART Patients Not Receiving ART

Article Tools

Search for Related Articles

Press Release

Unique Collaboration Charts the Migrations of a Parasite that Affected History
Researchers Sequence Louse DNA from Mummies and Propose New Model for its Development


In the News

Featured in U.S. News & World Report
"Common Cold Virus Alters Body's Genes" October 24, 2008
Comparison of the Safety and Immunogenicity of 2 Respiratory Syncytial Virus (RSV) Vaccines— Nonadjuvanted Vaccine or Vaccine Adjuvanted with Alum—Given Concomitantly with Influenza Vaccine to High-Risk Elderly Individuals
Ann R. Falsey, Edward E. Walsh, Jose Capellan, Stefan Gravenstein, Maria Zambon, Eddy Yau, Geoffrey J. Gorse, Robert Edelman, Frederick G. Hayden, Janet E. McElhaney, Kathleen M. Neuzil, Kristen L. Nichol, Eric A. F. Simões, Peter F. Wright, and Valérie M.-P. Sales
A second study, this one published in the Nov. 15 issue of The Journal of Infectious Diseases, found that respiratory syncytial virus, the main cause of lung infections and hospitalizations in children, may actually linger in the body even after symptoms subside.

Featured in Reuters-USE_THIS
"HPV infection rates similar in men and women" October 10, 2008
Age-Specific Prevalence, Incidence, and Duration of Human Papillomavirus Infections in a Cohort of 290 US Men
Anna R. Giuliano, Beibei Lu, Carrie M. Nielson, Roberto Flores, Mary R. Papenfuss, Ji-Hyun Lee, Martha Abrahamsen, and Robin B. Harris
Although men are at high risk of acquiring human papillomavirus (HPV) infections, most last no more than a year, about the same time this sexually transmitted disease persists in women, researchers report in The Journal of Infectious Diseases.

Featured in Houston Chronicle
"Graedons: Some food combos can do harm" August 10, 2008
Medical-Grade Honey Kills Antibiotic-Resistant Bacteria In Vitro and Eradicates Skin Colonization
Paulus H. S. Kwakman, Johannes P. C. Van den Akker, Ahmet Güçlü, Hamid Aslami, Jan M. Binnekade, Leonie de Boer, Laura Boszhard, Frederique Paulus, Pauline Middelhoek, Anje A. te Velde, Christina M. J. E. Vandenbroucke-Grauls, Marcus J. Schultz, and Sebastian A. J. Zaat
Honey has been used for thousands of years to help heal wounds. A recent article demonstrated that medical-grade honey kills antibiotic-resistant bacteria (Clinical Infectious Diseases, June 1, 2008). When applied to the forearm, this special Dutch honey (Revamil) kept germs from growing on the skin. The manufacturer also has developed a veterinary formulation called Vetramil, which is supposed to discourage licking.

Featured in Scientific American
"Stomach Bug May Ward Off Asthma" July 16, 2008
Helicobacter pylori Colonization Is Inversely Associated with Childhood Asthma
Yu Chen, Martin J. Blaser
"...scientists analyzed data from more than 7,000 participants in a national health and nutrition survey. They found that children between the ages of three and 13 are less than half as likely to have asthma if they carry H. pylori. They also had half the incidence of hay fever and other allergies. The results appear online in the July 15th issue of The Journal of Infectious Diseases."

Featured in U.S. News & World Report
"Stomach Germ May Protect Against Asthma" July 15, 2008
Helicobacter pylori Colonization Is Inversely Associated with Childhood Asthma

Yu Chen, Martin J. Blaser
"A stomach bacterium called Helicobacter pylori may reduce a child's risk of developing asthma by as much as 50 percent, a new study suggests.  H. pylori has been present in the human stomach probably since humans were humans. However, the germ began disappearing over the course of the 20th century with the introduction of antibiotics and cleaner water and homes, perhaps making children more susceptible to asthma, the study authors suggested."

Featured in Wired News
"Internal Bacterial Imbalance Leads to Asthma" July 15, 2008
Helicobacter pylori Colonization Is Inversely Associated with Childhood Asthma
Yu Chen, Martin J. Blaser
"In a study published yesterday in the Journal of Infectious Diseases, researchers showed that Heliobacter pylori, an intestinal microbe that co-evolved with humans, appears to protect children from asthma.  Asthma rates have nearly doubled in the United States since 1970, and are swelling in the developing world. Underlying the rise is a constellation of causes -- and one of these may be the loss of H. pylori, a vanishing member of the rich bacterial ecosystems in our stomachs."

Featured in Reuters
"Zinc reduces common cold symptoms" April 17, 2008
Duration and Severity of Symptoms and Levels of Plasma Interleukin-1 Receptor Antagonist, Soluble Tumor Necrosis Factor Receptor, and Adhesion Molecules in Patients with Common Cold Treated with Zinc Acetate
Ananda S. Prasad, Frances W. J. Beck, Bin Bao, Diane Snell, and James T. Fitzgerald
Zinc acetate lozenges taken within 24 hours of developing symptoms of the common cold reduce the duration and severity of symptoms, according to a report in The Journal of Infectious Diseases.

Featured in National Public Radio
"Peruvian Mummies' Lice Came from Africa" February 7, 2008
Molecular Identification of Lice from Pre-Columbian Mummies

Didier Raoult, David L. Reed, Katharina Dittmar, Jeremy J. Kirchman, Jean-Marc Rolain, Sonia Guillen, and Jessica E. Light
When humans migrated out of Africa 100,000 years ago, they were likely carrying stowaways. Scientists who've tested head lice taken from Peruvian mummies found the strains of these little parasites were nearly identical to those that were irritating our ancestors in Africa.

Featured in New York Times
"Scientists Say Mummies' Lice Show Pre-Columbian Origins" February 7, 2008
Molecular Identification of Lice from Pre-Columbian Mummies
Didier Raoult, David L. Reed, Katharina Dittmar, Jeremy J. Kirchman, Jean-Marc Rolain, Sonia Guillen, and Jessica E. Light
[In a new paper for the JID, scientists] establish that lice had accompanied their human hosts in the original peopling of the Americas, probably as early as 15,000 years ago. The DNA matched that of the most common type of louse known to exist worldwide now and also before Europeans colonized the New World.

Featured in Reuters
"Head lice came with us out of Africa" February 6, 2008
Molecular Identification of Lice from Pre-Columbian Mummies
Didier Raoult, David L. Reed, Katharina Dittmar, Jeremy J. Kirchman, Jean-Marc Rolain, Sonia Guillen, and Jessica E. Light
Head lice taken from 1,000-year-old mummies in Peru support the idea that the little creatures accompanied humans on their first migration out of Africa, 100,000 years ago, researchers reported on Wednesday.

15 April 2008

Volume 197, Number 8
The Journal of Infectious Diseases 2008;197:1133–1144
0022-1899/2008/19708-0010$15.00
DOI: 10.1086/586713
MAJOR ARTICLE

Major Clinical Outcomes in Antiretroviral Therapy (ART)–Naive Participants and in Those Not Receiving ART at Baseline in the SMART Study

The Strategies for Management of Antiretroviral Therapy (SMART) Study Groupa

Background.  The SMART study randomized 5472 human immunodeficiency virus (HIV)–infected patients with CD4+ cell counts >350 cells/μL to intermittent antiretroviral therapy (ART; the drug conservation [DC] group) versus continuous ART (the viral supression [VS] group). In the DC group, participants started ART when the CD4+ cell count was <250 cells/μL. Clinical outcomes in participants not receiving ART at entry inform the early use of ART.

Methods.  Patients who were either ART naive ( ) or who had not been receiving ART for 6 months ( ) were analyzed. The following clinical outcomes were assessed: (i) opportunistic disease (OD) or death from any cause (OD/death); (ii) OD (fatal or nonfatal); (iii) serious non-AIDS events (cardiovascular, renal, and hepatic disease plus non–AIDS-defining cancers) and non-OD deaths; and (iv) the composite of outcomes (ii) and (iii).

Results.  A total of 477 participants (228 in the DC group and 249 in the VS group) were followed (mean, 18 months). For outcome (iv), 21 and 6 events occurred in the DC (7 in ART-naive participants and 14 in those who had not received ART for 6 months) and VS (2 in ART-naive participants and 4 in those who had not received ART for 6 months) groups, respectively. Hazard ratios for DC vs. VS by outcome category were as follows: outcome (i), 3.47 (95% confidence interval [CI], 1.26–9.56; ); outcome (ii), 3.26 (95% CI, 1.04–10.25; ); outcome (iii), 7.02 (95% CI, 1.57–31.38; ); and outcome (iv), 4.19 (95% CI, 1.69–10.39; ).

Conclusions.  Initiation of ART at CD4+ cell counts >350 cells/μL compared with <250 cells/μL may reduce both OD and serious non-AIDS events. These findings require validation in a large, randomized clinical trial.

Trial registration.  ClinicalTrials.gov identifier: NCT00027352.

Received 8 June 2007; accepted 7 November 2007; electronically published 26 March 2008.

Reprints or correspondence: Dr. Sean Emery, Therapeutic and Vaccine Research Program, National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 376 Victoria St., Sydney, NSW 2010, Australia ()

Cited by

Timothy J. Wilkin and Roy M. Gulick. (2008) HIV/AIDS: When to Start Antiretroviral Therapy?. Clinical Infectious Diseases 47:12, 1580-1586
Online publication date: 15-Dec-2008.
A. Leon, E. Martinez, A. Milinkovic, B. Mora, J. Mallolas, J. L. Blanco, M. Larrousse, M. Laguno, T. Gallart, M. Plana, J. M. Gatell, F. Garcia. (2008) Influence of repeated cycles of structured therapy interruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption. Journal of Antimicrobial Chemotherapy
Online publication date: 11-Dec-2008.
CrossRef
Andrew N Phillips, James Neaton, Jens D Lundgren. (2008) The role of HIV in serious diseases other than AIDS. AIDS 22:18, 2409-2418
Online publication date: 1-Dec-2008.
CrossRef
A. C. Bailey, M. Fisher. (2008) Current use of antiretroviral treatment. British Medical Bulletin 87:1, 175-192
Online publication date: 1-Sep-2008.
CrossRef
Michael D. Hughes and Heather R. Ribaudo. (2008) The Search for Data on When to Start Treatment for HIV Infection. The Journal of Infectious Diseases 197:8, 1084-1086
Online publication date: 15-Apr-2008.
  • Financial support: SMART was supported by grants from the National Institute of Allergy and Infectious Diseases (U01AI68641, U01AI042170, and U01AI46362). The National Centre in HIV Epidemiology and Clinical Research is funded by the Australian Federal Department of Health and Ageing and is affiliated through the Faculty of Medicine with The University of New South Wales.

  • (See the editorial commentary by Hughes and Ribaudo, on pages 1084–6.)

  • aStudy group members (including the members of the Writing Group, who authored this article), conflicts of interest, and the role of the funding source are listed after the text.

Close Popup